Ten‐year outcomes after percutaneous coronary intervention of in‐stent restenosis in saphenous vein grafts
Catheterization and Cardiovascular Interventions · 2023
DOI: 10.1002/ccd.30807 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2023. Verfasst von Constantin Kuna und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Saphenous Vein, Coronary Restenosis, Graft Occlusion, Vascular, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Only few data is available for long‐term outcomes of patients being treated for in‐stent restenosis (ISR) in saphenous vein grafts (SVG).
Aims
Thus, the aim of this observational, retrospective study was to close this lack of evidence.
Methods
Between January 2007 and February 2021 a total of 163 patients with 186 ISR lesions located in SVG were treated at two large‐volume centers in Munich, Germany. Endpoints of interest were all‐cause mortality, target lesion revascularization (TLR) and target vessel myocardial infarction (TVMI). Furthermore, recurrent ISR were assessed. Outcomes are presented as Kaplan–Meier event rates.
Results
Mean age was 72.6 ± 8.6 years, 90.8% were male, 36.8% were diabetics and 42.3% presented an acute coronary syndrome. ISR were treated with DES in 64.0% and with balloon angioplasty (BA) in 36.0%. After 10 years, the rates for all‐cause mortality, TVMI and TLR were 58.2%, 15.4%, and 22.6%, respectively. No statistically relevant differences were found between the types of treatment (DES or BA) regarding all‐cause mortality (55.7% vs. 63.2%, p = 0.181), TVMI (13.8% vs. 18.6%, p = 0.215) and TLR (21.8% vs. 25.0%, p = 0.764). Median time between first and recurrent ISR was 270.8 days. Recurrent ISR were treated with DES in a comparable proportion as during first ISR ( p = 0.075). Independent predictor of TLR is patient age ( p = 0.034). The median follow‐up duration was 5.1 years (75% CI 2.8; 8.5).
Conclusions
Clinical event rates after intervention of ISR located in SVG are high without statistically relevant differences regarding the type of treatment. However, further studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
- Clinic and Policlinic Internal Medicine I (Cardiology and Angiology), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
ORCID-Profile: Constantin Kuna, Salvatore Cassese, Adnan Kastrati
Zitieren
APA
Kuna, C., Wiedenmayer, N., Bradaric, C., Presch, A., Voll, F., Kufner, S., Ibrahim, T., Schunkert, H., Laugwitz, K. L., Cassese, S., Kastrati, A., & Wiebe, J. (2023). Ten‐year outcomes after percutaneous coronary intervention of in‐stent restenosis in saphenous vein grafts. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30807
Vancouver
Kuna C, Wiedenmayer N, Bradaric C, Presch A, Voll F, Kufner S, et al. Ten‐year outcomes after percutaneous coronary intervention of in‐stent restenosis in saphenous vein grafts. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30807
BibTeX
@article{Kuna2023,
author = {Kuna, Constantin and Wiedenmayer, Nadine and Bradaric, Christian and Presch, Antonia and Voll, Felix and Kufner, Sebastian and Ibrahim, Tareq and Schunkert, Heribert and Laugwitz, Karl-Ludwig and Cassese, Salvatore and Kastrati, Adnan and Wiebe, Jens},
title = {Ten‐year outcomes after percutaneous coronary intervention of in‐stent restenosis in saphenous vein grafts},
journal = {Catheterization and Cardiovascular Interventions},
year = {2023},
doi = {10.1002/ccd.30807}
}
EUVIMED